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1. Introduction 
The term "Diabetes mellitus" encompasses a heterogeneous group of disorders characterized 
by insulin hyposecretion and/or insensitivity. 
Type 1 DM is a chronic autoimmune disease associated with selective destruction of insulin-
producing pancreatic b-cells. A variety of gene loci have been studied to determine their 
association with type 1 DM. The early studies suggested that the B8 and B15 of HLA class I 
antigens were increased in frequency in the diabetics compared to the control group. 
However, more recently the focus has shifted to the class II HLA-DR locus. It was found that 
DR3 and DR4 were more prevalent than HLA-B in type 1.DM than HLA-B. The nature of 
autoantigen(s) responsible for the induction of type 1 DM is unknown. The identification of 
autoantigens in type 1 DM is essential both for diagnostic purposes and for potential 
immunotherapeutic intervention in the disease process. 
Type 2 DM has a greater genetic association than type 1 DM. The 100% concordance rate in 
identical twins is thought to be overestimated, due to a selection or reporting bias. A 
population based twin study in Finland has shown a concordance rate of 40%. 
Environmental effect may be a possible reason for the higher concordance rate for type 2 
DM than for type 1 DM. Perturbations in glucose metabolism due to insulin resistance are 
further exacerbated when insulin production is compromised.Insulin resistance is a 
characteristic feature of most patients with Type 2 diabetes mellitus.Several cross-sectional 
studies in non diabetic subjects on the general population or in individuals with impaired 
glucose tolerance (IGT)/impaired fasting glucose (IFG) have confirmed that acute-phase 
reactants such as CRP (and sometimes the cytokines IL-6 and TNF-ǂ) are positively 
correlated with measures of insulin resistance/plasma insulin concentration, BMI/waist 
circumference, and circulating triglyceride and negatively correlated with HDL cholesterol 
concentration. In general, increasing components of the metabolic syndrome in individuals 
are associated with higher levels of inflammatory markers. 
In subjects with IGT or IFG, IL-6 but not TNF-ǂ appears to be elevated compared with 
individuals with normal glucose tolerance and in one study, inflammatory markers were 
related to insulin resistance but not to insulin secretion . 
Psoriasis is a chronic inflammatory disease of the skin, scalp, nails, and sometimes  joints 
that affects 1-2 percent of the general population.Psoriasis is a clinical diagnosis. The disease 
is characterized by erythematous and indurate plaque which usually are covered by thick 
silvery white scales and can manifests as psoriatic arthritis (PsA), an inflammatory joint 
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disease resulting in extensive bone resorption and joint destruction. Although the clinical 
course of psoriasis is highly variable between individuals, the lesions are typically recurrent. 
The aim of this study is to define the linkage between psoriasis and diabetes.There has been 
performed a retrospective study (cross- sectional study). The data used in this study were 
obtained from the University Hospital Center “Mother Teresa” in Tirana. Being the only 
University Hospital Center, it admits as well patients from other districts of Albania. 
Clinical files of the patients from moderated to severe psoriasis, hospitalized in the 
dermatology clinic during the period 2000-2010, have been examined. Control group are 
been considered other hospitalized non psoriasis cases in this hospital center. Both groups 
had its glycemia values recorded..T-test (student test) was used to compare the continuous 
variables while the statistical analysis was performed by using SPSS software. 
2. Genetics of psoriasis 
Associations between psoriasis and particular HLA types have been recognized for nearly 
30 years. Henseler and Christophers defined type I psoriasis as having age of onset younger 
than 40 years, with strong HLA associations. Patients with type II disease were 
characterized by age of onset 40 years or older, and much weaker HLA associations Patients 
with type I disease showed a much stronger tendency for familial involvement.The risk ratio 
for first-degree relatives was approximately 10 for patients with type I psoriasis, but only 
about 1 to 2 for those with type II psoriasis.  
The HLA associations identified in the study of familial psoriasis by James T et al. are very 
similar to those identified in previous case-control studies of HLA association in psoriasis.In 
particular, strong associations with HLA-Cw6 and HLA-B57 were found. Approximately 
two thirds of the psoriatic patients in those earlier studies had a family history negative for 
psoriasis and could be assumed to represent sporadic cases. The similarity of the HLA 
associations obtained in pedigree and case-control studies implies that so-called sporadic 
psoriasis must also have a genetic basis. Because no other inflammatory disease manifests 
such a strong HLA-C association, it suspect that the MHC psoriasis gene is a disease-specific 
gene. 
The study of Houglin  Wang et al confirmed that a locus on chromosome 10,  drives the 
development of psoriasiform skin disease as well as arthritis in the presence of low 
expression of the common chain of ǃ2 integrins (CD18).They show that a congenic strain 
containing the 9-cM PL/J element on chromosome 10 (D10mit126 to D10mit194), designated 
as chromosome 10B PSD1 congenic strain, on the resistant C57BL/6J CD18hypo background 
developed psoriasiform skin disease, and most notably also a severe arthritis of joints. The 
PL/J background in the presence of low CD18 expression drives the development of 
psoriasiform skin disease but rarely in combination with arthritis. 
In contrast, the two produced congenic strains harboring fragments telomeric and 
centromeric of the 9-cM PSD1 fragment (chromosomes 10A and 10D) did not develop the 
psoriasiform skin disease and/or arthritis within an observation period of 10 mo. These data 
indicate that a gene (or genes) within the PSD1 locus contribute(s) to pathogenic events 
common to the psoriasiform skin disease and arthritis in this context under the condition of 
low expression of CD18.  
Since the chromosome 10C mice, congenic for a larger fragment of the chromosome 10 
including the PSD1 locus, developed a phenotype identical to the PSD1 congenic 
(chromosome 10B),  they conclude that the PSD1 locus is the major locus within that region. 
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It is estimated that approximately 40% of individuals suffering from psoriasis or psoriatic 
arthritis   
(PsA) have a first-degree relative who has the disease. In addition, concordance rates as high 
as 70% have been reported among identical twins. Given the strong genetic component of 
psoriasis, patients who have psoriasis are often concerned about the heritability of the 
disease. Family studies indicate that if both parents have psoriasis then the offspring have a 
50% chance of developing the disease; if only one parent has psoriasis then the risk for a 
child to develop psoriasis is 16%. If neither parent is affected but a child develops psoriasis 
then his/her siblings have an 8% risk for developing the disease. Men have a higher risk for 
transmitting psoriasis to offspring than women, likely because of genomic imprinting, 
which is an epigenetic effect that causes differential expression of a gene depending on the 
gender of the transmitting parent .Because genetics are immutable, modifiable 
environmental risk factors for psoriasis are of special interest. Further efforts to identify the 
long –sought gene/genes involving in the pathogenesis of psoriasis continue. 
3. Risk factors 
There are several risk factors that may provide the environmental stimulus for T-cell 
proliferation leading to the development of psoriasis. They include psychological stress, 
certain medication such as antimalarial drugs, beta blockers , lithium  and non steroidal, 
anti-inflammatory drugs ,a history of skin infection, obesity ,smoking and alcohol 
consumption . 
3.1 Stessful like events (psychological stress) 
The recognition of psychological needs in patients  with psoriasis is critical for managing the 
condition. Psoriasis can have a substantial psychological and emotional impact on an 
individual, which is not always related to the extent of skin disease. There are elevated rates 
of various psychopathologies among patients with psoriasis including poor self-esteem, 
sexual dysfunction, anxiety, depression, and suicidal ideation.   
In different studies (most of them are retrospective ) from about one third to about three 
fourth of psoriatics believed that  there was a stress worsening of their psoriasis.The results  
of an other study do not indicate a major significance of stress  for plaque psoriasis patients. 
But  this was a small study. The clinical severity of psoriasis may not reflect the degree of 
emotional impact of the disease. Still it cannot be ruled out that stress may be an important 
factor for some psoriasis patients. 
3.2 Smoking 
An increased prevalence of smoking among patients with psoriasis has been observed in 
numerous countries including Finland, Italy, the United Kingdom, Norway, China, and the 
United States. Cigarette smoking has been shown to correlate with increased disease 
severity and increased mortality in causes of death related to smoking in patients with 
psoriasis. 
In a study, 35 patients who smoked more than 10 cigarettes per day had more severe 
psoriasis affecting both forearms, hands and feet compared with non smokers (all P<0.05). 
Studies have proposed different mechanisms that could link nicotine to psoriasis, including 
the enhancement of pro-inflammatory cytokines and altered morphology and functionality 
of leukocytes. 
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3.3 Alcohol consumption 
Multiple studies have shown that increased alcohol use, and  in some cases, abuse, are 
independent risk factors for psoriasis.A positive dose-response relationship between alcohol 
intake and psoriasis severity in women was seen in one prospective questionnaire-based 
study.  
Several studies have evaluated the link between psoriasis and alcoholism. However , further 
study is needed  to determine  whether  an increase in alcohol consumption  is a primary 
risk factor for the development of psoriasis ,or whether alcohol abuse is a secondary factor 
related to psychosocial  rejection that some psoriasis patients may experience. 
3.4 Obesity 
Over the last decade, studies showed a chronic condition of mild inflammation caused by 
obesity, with high levels of TNF-ǂ, IL-6, and C-reactive protein associated with an increase 
of BMI. Obesity could play a role in the development of psoriasis, based on the pro-
inflammatorystate it provokes. Or perhaps it could be a consequence of psoriasis, caused by 
metabolic deregulations induced by the pro-inflammatory state, associated with a poor 
quality of life and inadequate food habits of the disease carrier. 
3.5 Medication 
Psoriasis and psoriasiform eruptions have also been associated with use of other 
antihypertensive such as angiotensin II (AT II) antagonists, calcium channel blockers (CCBs) 
or clonidine. 
Beta-blockers and ACE inhibitors are widely used drugs for the treatment of hypertension, a 
disease which has been associated with psoriasis, but there is no consensus on the 
mechanism by which beta-blockers might induce such a reaction. 
3.6 Infections 
Microorganisms have been associated to the development of psoriasis. ǃ-hemolytic 
streptococcal infections are linked to the development of guttate psoriasis and intercurrent 
infections have been associated to pustular psoriasis flares. Streptococcal antigens have been 
reported, suggesting an autoimmune component in the disease. Protective immunity against 
streptococci is therefore likely to be dependent on both CD4+ and CD8+ T cells. It is of 
interest, in this context, that both CD4+ and CD8+ T cells isolated from psoriatic skin lesions 
have been shown to be respond to crude streptococcal antigens. 
4. Imuno-pathogenesis of psoriasis 
Despite its unknown etiology, there have been break throughs in the understanding of the 
immunopathogenesis of psoriasis in recent years. It is now almost certain that psoriasis is a 
T-lymphocyte mediated inflammatory dermatosis with hyper-proliferation of keratinocytes 
in genetically predisposed subjects.  
At the cellular level, psoriasis is characterized by markedly increased epidermal 
proliferation and incomplete differentiation; elongation, dilatation and “leakiness” of the 
superficial plexus of dermal capillaries; and a mixed inflammatory and immune cell 
infiltrate of the epidermis and papillary dermis. 
It is now believed that the clinical phenotype of psoriatic skin arises from the interplay 
between inflammatory cytokines and cells that make up the cutaneous microenvironment 
(ie, lymphocytes, antigen-presenting cells [APCs], endothelial cells, and keratinocytes).  
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Th1 lymphocytes have been identified as a primary source of inflammatory cytokine 
production in psoriatic skin; regulatory T cells, which normally suppress effector T-cell 
activity, are dysfunctional in the blood and skin of patients who have psoriasis; and recently 
identified Th17 cells produce the cytokine interleukin (IL)-17, which is critical to the 
establishment and maintenance of autoimmunity, and IL-22, which is primarily involved in 
the process of epidermal differentiation and hyperproliferation. APCs (ie, plasmacytoid and 
myeloid dendritic cells) and endothelial cells lining the dermal microvasculature have also 
been shown to play a role in psoriatic disease. In particular, dermal dendritic cells have been 
shown to contribute to the production of Th1 cytokines (such as IFN-ǂ ,TNF-ǂ and IL-2)and 
the recruitment of inflammatory cells into psoriatic plaques. The production of IL-20 and IL-
23 by myeloid dendritic cells has been reported to promote keratinocyte proliferation, up-
regulate inflammatory gene products, and stimulate T-cell activation, all of which contribute 
to psoriatic lesions. Endothelial cells play a critical role in recruiting inflammatory cells 
through their expression of E-selectin, which enhances the homing of cutaneous 
lymphocyte-associated antigen- positive T cells into the skin. Angiogenesis is stimulated by 
the inflammatory process and studies demonstrate that circulating levels of vascular 
endothelial growth factor correlate with psoriasis activity. 
5. Psoriasis and comorbidities 
The multiaspect nature of psoriasis as a systemic disease associated with numerous 
multiorgan abnormalities and complications has been recognized. 
Many epidemiologic studies with varies designs  link psoriasis to systemic metabolic co-
morbidities. Psoriasis and its comorbidities share a common etiological linkage, it is 
hypothesized that proinflammatory cytokines contribute to dyslipidemias, atherogenesis, 
peripheral insulin resistance, type II diabetes, hypertension etc. 
5.1 Cardiovascular risk in patients with psoriasis 
Several studies have demonstrated that cardiovascular diseases and their associated risk 
factors are more common in patients with psoriasis than in the general population. The 
cause of this elevated risk is unclear. Severe psoriasis is associated with an increased 
prevalence of metabolic syndrome. Metabolic syndrome is generally defined by the presence 
of or treatment for at least three of the following five criteria: hypertension, insulin 
resistance, decreased high-density lipoprotein, hypertriglyceridemia, and central obesity.  
Mallbris et al. performed a historical cohort study to assess the risk for cardiovascular 
mortality among psoriasis patients. These data suggest on the one side, that psoriasis 
patients with more severe disease have a substantially increased risk for cardiovascular 
death. On the other side, it can be argued that the available in-hospital treatment modalities 
contribute to this risk as well. 
The increased risk of MI and vaso-occlusive disease was attributed to the increased 
prevalence of risk factors in psoriatic patients including lifestyle factors such as smoking 
and alcohol abuse. Evolving research suggests that the chronic inflammatory nature of 
psoriasis itself may lead to adverse health outcomes, including coronary artery disease and 
myocardial infarction (MI). 
Several cytokines that have been identified as important mediators of psoriasis, such as 
interleukins 1, 4, 6, 8, 12 and tumor necrosis factor-ǂ , have also been identified in metabolic 
syndrome, a chronic inflammatory state associated with obesity. Given the link between 
atherosclerosis  and inflammation ,the risk of cardiovascular disease is likely to be increased 
in patients with psoriasis. 
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Psoriasis and atherosclerosis may have certain common underlying pathogenic  
mechanisms.A separate prospective study demonstrated an increased relative risk for 
myocardial infarction compared to healthy controls; this increased risk was greater in 
younger patients with mild or severe psoriasis, compared to older patients with similar 
severity of disease. 
Epidemiologic studies show that atherosclerosis has a number of causal risk factors, several 
of which(Cigarette smoking, atherogenic lipids, hypertension, and hyperglycemia) involve 
cytokines, other bioactive substances, and cells characteristic of the inflammatory process. 
Gelfand JM, et al.54 had conducted a population-based cohort study using data collected by 
general practitioners participating in the General Practice Research Database in the United 
Kingdom from 1987- 2002. A total of 556,995 control patients and patients with mild (n = 
127,139) and severe psoriasis (n = 3,837) were studied, and controlled for traditional 
cardiovascular risk factors (diabetes mellitus, history of myocardial infarction (MI), 
hypertension, hyperlipidaemia, smoking). They found that the adjusted relative risks of MI 
are 1.54 (1.24–1.91) and 7.08 (3.06-16.36) respectively in mild and severe psoriasis as 
compared with controls. 
Diabetes and related metabolic diseases, such as hyperinsulinemia, insulin resistance, and 
central obesity, are recognized as major contributors to cardiovascular morbidity and 
mortality. Psoriasis is known to be associated with several lifestyle factors  such a smoking, 
obesity and diabetes that per se  may  increase the risk of cardiovascular morbidity. 
5.2 Obesity and diabetes in patients with psoriasis  
Psoriasis has a complex relationship with metabolic diseases such as obesity. 
Studies have shown that, compared with the general population , patients with psoriasis  
are more frequently overweight ( 25≤BMI<30) or obese (BMI>30). 
Adipose tissue, including adipocytes and resident macrophages, may serve as a significant 
source of TNF-ǂ. TNFa is a pro-inflammatory cytokine that amplifies inflammation through 
several distinct pathways: facilitating entry of inflammatory cells into lesional skin through 
induction of adhesion molecules on vascular endothelial cells; stimulating keratinocyte 
production of other pro-inflammatory mediators. 
Risk for psoriasis has been shown to increase with increasing BMI (P=0.001). This pro-
inflammatory state in obesity may explain the association between psoriasis and obesity and 
these proinflammatory cytokines might also influence the course and presentation  of 
psoriasis. .In a study performed by Halla M. Ragab et al., with increase of the severity of the 
disease, these cytokines are significantly elevated in severe psoriasis patients than in mild to 
moderate one which is attributed to the role of these cytokines in the pathogenesis and 
progress of psoriasis and their elevation is responsible for the development, maintenance 
and resolution of psoriatic lesions. When patients with psoriasis are more likely to be obese 
that implies they will also have the comorbid conditions of those with obesity. The risks of 
diabetes, hypertension and dyslipidemia start to rise from a BMI of about 21.0 kg/m2 there 
by deteriorating the cardiovascular risk profile. 
Inflammation plays a role in the pathogenesis of some glucose disorders in adults.Obesity 
has genetic as well as environmental causes. It has a strong effect on the development of 
type 2 DM, as it is found in western countries and some ethnic groups such as Pima Indians. 
Obesity is more than just a risk factor, it has a causal effect in the development of type 2 DM 
against a genetic background. The evolution from obesity to type DM results from a 
succession of pathophysiological events: (a) augmentation of the adipose tissue mass, 
leading to increased lipid oxidation; (b) insulin resistance noted early in obesity, revealed by 
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euglycemic clamp, as a resistance to insulin mediated glucose storage and oxidation. 
Blocking the function of the glycogen cycle; (c) despite maintained insulin secretion, unused 
glycogen prevents further glucose storage leading to type 2 DM; (d) complete b-cell 
exhaustion appears later. 
Also, studies have reported a high prevalence of  diabetes among  patients with psoriasis. 
Joshua Barzilay (Tucker, GA) reviewed the association of markers of inflammation with 
diabetes.  Inflammation is strongly related to insulin resistance, although the question of 
whether treatment directed at the inflammatory process could lead to benefits, such as 
decreasing the development of diabetes, has yet to be answered.In a study of 200  patients 
with psoriasis  at an Italian clinic  reported  that  41.5% had diabetes compared with  24.3 % 
of controls ( n=280; P< 0.001). Of note,  36.7%  of psoriasis patients  younger  than  50 years  
of age (n=117) had diabetes (P< 0.001). Studies  have shown that patients with psoriasis  
have higher  rates of impaired glucose tolerance compared with  controls(all P<0.05). 
5.3 HTA in patients with psoriasis 
Several epidemiologic studies have shown that hypertension is a common comorbidity in 
patients with psoriasis. An increased risk of hypertension of 1.2- to 2-fold has been reported 
in cross-sectional studies. 
As mentioned above, psoriasis is a chronic inflammatory disease, and inflammation is a risk 
factor for hypertension. Systemic treatments in psoriasis reduce the cardiovascular risk by 
diminishing the inflammation, but it should be taken into account that most therapies also 
have adverse cardiovascular effects like dyslipidemia, hyperhomocysteinemia and 
hypertension. 
6. Results of the study 
This study covered 599 psoriatic patients  (3-80 yrs old) and 599 cases of control group ( 3-85 
yrs old). The age average for both groups varies in 49.64, with a SD value= 19.179 and 
median value of  M=53.00. (Tab.1,2,3) 
 
Grupi
599 50.0 50.0 50.0
599 50.0 50.0 100.0
1198 100.0 100.0
Kontroll
Psoriasis
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
 
Table 1. Frequency 
 
Seksi
711 59.3 59.3 59.3
487 40.7 40.7 100.0
1198 100.0 100.0
M
F
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
 
Table 2. Seksi 
The mean glycemia value for both groups was in the value 105.31 with a Standard Deviation 
value of 38.641 and median value of M= 96.00 
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Statistics
1198 1198
0 0
49.64 105.31
53.00 96.00
19.179 38.641
Valid
Missing
N
Mean
Median
Std. Deviation
Mosha Glicemia
 
Table 3. Statistic 
The outcome of the statistical analysis for both groups provided a mean value of glycemia in 
the control group of 106.98±41.700 and in the psoriasis group of 103.64±35.275 (Tab.4) 
 
Group Statistics
599 106.98 41.700 1.704
599 103.64 35.275 1.441
Grupi
Kontroll
Psoriasis
Glicemia
N Mean Std. Deviation
Std. Error
Mean
 
Table 4. Group Statistic 
T-Test equality outcome showed that there is no statistical significant difference 
(considerable) in glycemia  values between psoriatic group and control group (P=0.134). 
(Tab.5) 
 
Independent Samples Test
1.498 1196 .134 3.344 2.232 -1.034 7.722
1.498 1164.005 .134 3.344 2.232 -1.035 7.722
Equal variances
assumed
Equal variances
not assumed
Glicemia
t df Sig. (2-tailed)
Mean
Difference
Std. Error
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
 
Table 5. Independent Samples Test 
7. Discussion 
7.1 Are psoriasis and diabetes linked? 
Psoriasis and diabetes have a certain common underlying pathogenic mechanisms. Both 
have an inflammatory nature and both are associated with T-lymphocite –mediated 
adaptive immune events and mechanisms, involving innate immunity. Specifically, both 
psoriasis and diabetes are associated with T-helper. 
Th-1 inflammatory cytokines such as TNF-a  are elevated in the skin and blood of patients 
with psoriasis and diabetes .(table-.6) Similarly, TNF-a is secreted in adipose tissue and is an 
important feature of the chronic low level inflammation seen in obesity Insulin resistance, 
which is common to psoriasis and the metabolic syndrome, may be mediated in part 
through inflammatory cytokines such as TNF. 
The adipocyte is another important component of inflammation. Adipose tissue secretes 
inflammatory cytokines such as TNF-ǂ and IL-6, and CRP levels increase with increasing 
www.intechopen.com
 
Psoriasis and Diabetes 
 
91 
weight.A new conceptis that obesity leads to macrophage infiltration of adipose tissues, 
perhaps because of the action of factors produced by adipocytes themselves, with 
macrophages rather than adipocytes producing some of the typically measured 
inflammatory cytokines. In this view, macrophages may produce factors such as TNF-ǂ, 
causing insulin resistance, while both macrophages and adipocytes produce factors that 
increase hepatic CRP synthesis, such as IL-6.9 (Table-6). 
Other cells and biologically active molecules (including cytokines, chemokines, adipokines) 
that are implicated in the pathogenesis of both psoriasis and diabetes are listed and 
referenced in Table 6. 
A major problem limiting our understanding of the genetic basis of type 2 diabetes is that 
many environmental and genetically based factors influence insulin sensitivity and insulin 
secretion: these include age, gender, ethnicity, physical fitness, diet, smoking obesity, and fat 
distribution.  
The prevalence of obesity, diabetes, and metabolic syndrome has been shown to be increased 
in psoriasis patients in the general population. At least one study has demonstrated a higher 
prevalence of diabetes in patients who have psoriasis independent of traditional diabetes risk 
factors such as age, gender, obesity, hypertension, and hyperlipidemia, indicating that the 
disease itself, or possibly its chronic treatments, may predispose to the development of 
diabetes.  
As early as 1950’s, there was epidemiological evidence suggesting a correlation between 
inflammation and insulin resistant states such as obesity, but the mechanistic links were 
unknown. In the last decade, however, it has become increasingly evident that obesity and 
the concomitant development of inflammation are major components of insulin resistance. 
Studies in human obesity and insulin resistance have revealed a clear association between 
the chronic activation of pro-inflammatory signaling pathways and decreased insulin 
sensitivity. For example, elevated levels of tumor necrosis factor-ǂ (TNF), interleukin-6 (IL-
6) and interleukin (IL-8) have all been reported in various diabetic and insulin-resistant 
states . We noticed a non significant difference in the glycemia values of our study of the 
psoriasis group vs non-psoriasis group. However it has to be pointed out that this study has 
not taken into consideration other factors like for instance obesity, fat level, HTA which play 
an important role in insulin resistance. In a cross-sectional study (performed by Reynoso-
von Drateln et al. ) on lipids profile, insulin secretion  and insulin sensitivity  at psoriatic 
patients it resulted that : high – density lipoprotein cholesterol was significantly decreased 
in patients with psoriasis  (p=0.2) .There were no significant differences  in insulin secretion 
or sensitivity in patients with psoriasis compared with control patients. 
The relationship between systemic treatment of psoriasis and CVR factors has not been 
adequately studied; however, in rheumatoid arthritis and psoriasis, systemic treatment with 
methotrexate has been shown to decrease vascular risk.Methotrexate (MTX) is a frequently 
prescribed agent.MTX blocks DNA synthesis in; rapidly proliferating epidermal cells, T- and 
B-lymphocytes and disrupts cytokine secretion. 
In our psoriasis patient group, the most applied therapy has been the one with Methotrexate 
and UV phototherapy due to the fact that the psoriasis encountered cases has been between 
middle and high degree. 
UV irradiation induces a degree of systemic immunosuppress mediated via a number of 
mechanisms possibly including production of Th2 cytokines interleukin(IL-4) and (IL-10). 
UV-induced vitamin D production  may also reduce risks for atherosclerosis in several ways 
including augmentation of IL-10 and downregulation of TNF-ǂ, C-reactive protein and IL-6 
production.  
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 Psoriasis Diabetes 
Cytokines  
IL-2 + + 
IL-1 (no) + 
IL-4 (no) + 
IL-5 (no) + 
IL-6 + + 
IL-10 (no) + 
IL-13 (no) + 
IL-15 + (no) 
IL-17 + (no) 
IL-18 + (no) 
IL-20 + (no) 
IL-23 + (no) 
IFN-ǂ + + 
IFN-y + + 
TNF-ǂ + + 
Chemokines  
IP-10 + + 
MCP-1 + + 
IL-8 + + 
Adipokines + + 
Resistin + + 
Leptin + + 
PAI-1 + + 
Adhesion and costimulatory molecules  
ICAM/LFA-1 + + 
VCAM-1/VLA-4 + + 
CD80,CD28 + (no) 
CD40/CD40L + (no) 
Leucocytes  
Th1 + + 
Th2 + + 
CD4 + + 
CD8 + + 
Monocytes/Macrophages + + 
Neutrophils + + 
Other molecules  
CRP + + 
iNOS + + 
Oxidized LDL + + 
CRP, C-reactive protein; IL interleukin; ICAM,intercellular adhesion molecule; IFN interferon; iNOS, 
inducible nitric oxide synthase; IP-10, interferon-inducible protein 10; LDL, low density lipoprotein; 
MCP-1 monocye chemotactic protein-1; PAI-1 plasminogen activator inhibitor type 1; TNF-ǂ, tumour 
necrosis factor-alfa; Th1/Th2, T-helper 1 and T-helper 2; VCAM-1, vascular cell adhesion molecule-1 
Table 6. Major inflammatory mediators in psoriasis and diabetes 
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8. Conclusion 
Our study is just an observation. Psoriasis is a very complex pathology both from the 
pathogenesis it provides as well as the ongoing and the complications that could be 
encountered. Therefore it is more and more necessary to perform studies on it and on the 
risks it carries on. 
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